Back to School: How biopharma can reboot drug development. Access exclusive analysis here

KB2115: Phase IIa data

In the double-blind, Swedish and Finnish Phase IIa KB003 trial in 98

Read the full 124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE